Table 2.

Fibrosis biomarkers concentrations in all PLN variant carriers (n = 72) or divided into ACM diagnosed (n = 12), DCM diagnosed (n = 14) or preclinical pathogenic variant carriers (n = 46).

	All PLN	ACM diagnosed	DCM diagnosed	Preclinical variant carrier	Adjusted
	(n = 72)	(n = 12)	(n = 14)	(n = 46)	p-value
PICP (ng/mL)	120.18 [98.32–146.98]	112.55 [95.19–135.32]	133.44 [104.91–156.28]	120.18 [98.62–144.72]	>0.999
ICTP (ng/mL)	3.14 [2.42–3.81]	3.34 [2.68–4.76]	3.36 [2.38–3.87]	3.07 [2.43–3.54]	>0.999
PICP/ICTP	42.40 [29.70–51.63]	37.74 [23.54–45.37]	43.70 [27.90–51.88]	42.57 [31.53–54.12]	>0.999

Data is shown as median [interquartile range]. PLN, phospholamban; ACM, arrhythmogenic cardiomyopathy; DCM, dilated cardiomyopathy; PICP, procollagen type I carboxy-terminal pro-peptide; ICTP, C-terminal telopeptide collagen type I. Kruskal wallis test is performed. Bonferroni correction is applied to correct p-value.